IKCS 2010: Activity of Tivozanib (AV-951) in Patients With Different Histologic Subtypes of Renal Cell Carcinoma

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)